Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bit Digital Inc (BTBT) vs Cassava Sciences Inc (FLNA) Price & Performance

Bit Digital IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Bit Digital Inc vs Cassava Sciences Inc — how do they compare? Bit Digital Inc trades at $1.66 (market cap $581.34M), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: Bit Digital Inc is far larger — about 11× Cassava Sciences Inc's market cap, and Bit Digital Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

BTBTFLNA
Market Cap
$581.34M$52.66M
Sector
TechnologyHealth
52-Week High
$4.22$4.64
52-Week Low
$1.27$1.09
Enterprise Value
$870.65M-$33.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bit Digital Inc

BTBT trades at $1.64, down 2.96% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $80.32 million in 2025 with a -145.45% net income margin, missing earnings expectations for three consecutive quarters. Recent strategic moves include a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase to bolster its asset position.

Despite 100% analyst buy ratings, BTBT faces significant fundamental challenges with persistent losses and negative cash flow from operations. The stock's appeal hinges on turnaround execution and crypto market recovery, but high volatility and operational risks warrant caution for investors.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

About Bit Digital Inc

Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.

Read more on BTBT

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA